Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
31
03
2021
revised:
21
04
2021
accepted:
27
04
2021
pubmed:
31
5
2021
medline:
5
10
2021
entrez:
30
5
2021
Statut:
ppublish
Résumé
The banning of mass-gathering indoor events to prevent SARS-CoV-2 spread has had an important effect on local economies. Despite growing evidence on the suitability of antigen-detecting rapid diagnostic tests (Ag-RDT) for mass screening at the event entry, this strategy has not been assessed under controlled conditions. We aimed to assess the effectiveness of a prevention strategy during a live indoor concert. We designed a randomised controlled open-label trial to assess the effectiveness of a comprehensive preventive intervention for a mass-gathering indoor event (a live concert) based on systematic same-day screening of attendees with Ag-RDTs, use of facial masks, and adequate air ventilation. The event took place in the Sala Apolo, Barcelona, Spain. Adults aged 18-59 years with a negative result in an Ag-RDT from a nasopharyngeal swab collected immediately before entering the event were randomised 1:1 (block randomisation stratified by age and gender) to either attend the indoor event for 5 hours or go home. Nasopharyngeal specimens used for Ag-RDT screening were analysed by real-time reverse-transcriptase PCR (RT-PCR) and cell culture (Vero E6 cells). 8 days after the event, a nasopharyngeal swab was collected and analysed by Ag-RDT, RT-PCR, and a transcription-mediated amplification test (TMA). The primary outcome was the difference in incidence of RT-PCR-confirmed SARS-CoV-2 infection at 8 days between the control and the intervention groups, assessed in all participants who were randomly assigned, attended the event, and had a valid result for the SARS-CoV-2 test done at follow-up. The trial is registered at ClinicalTrials.gov, NCT04668625. Participant enrollment took place during the morning of the day of the concert, Dec 12, 2020. Of the 1140 people who responded to the call and were deemed eligible, 1047 were randomly assigned to either enter the music event (experimental group) or continue with normal life (control group). Of the 523 randomly assigned to the experimental group, 465 were included in the analysis of the primary outcome (51 did not enter the event and eight did not take part in the follow-up assessment), and of the 524 randomly assigned to the control group, 495 were included in the final analysis (29 did not take part in the follow-up). At baseline, 15 (3%) of 495 individuals in the control group and 13 (3%) of 465 in the experimental group tested positive on TMA despite a negative Ag-RDT result. The RT-PCR test was positive in one case in each group and cell viral culture was negative in all cases. 8 days after the event, two (<1%) individuals in the control arm had a positive Ag-RDT and PCR result, whereas no Ag-RDT nor RT-PCR positive results were found in the intervention arm. The Bayesian estimate for the incidence between the experimental and control groups was -0·15% (95% CI -0·72 to 0·44). Our study provides preliminary evidence on the safety of indoor mass-gathering events during a COVID-19 outbreak under a comprehensive preventive intervention. The data could help restart cultural activities halted during COVID-19, which might have important sociocultural and economic implications. Primavera Sound Group and the #YoMeCorono Initiative. For the Spanish translation of the abstract see Supplementary Materials section.
Sections du résumé
BACKGROUND
The banning of mass-gathering indoor events to prevent SARS-CoV-2 spread has had an important effect on local economies. Despite growing evidence on the suitability of antigen-detecting rapid diagnostic tests (Ag-RDT) for mass screening at the event entry, this strategy has not been assessed under controlled conditions. We aimed to assess the effectiveness of a prevention strategy during a live indoor concert.
METHODS
We designed a randomised controlled open-label trial to assess the effectiveness of a comprehensive preventive intervention for a mass-gathering indoor event (a live concert) based on systematic same-day screening of attendees with Ag-RDTs, use of facial masks, and adequate air ventilation. The event took place in the Sala Apolo, Barcelona, Spain. Adults aged 18-59 years with a negative result in an Ag-RDT from a nasopharyngeal swab collected immediately before entering the event were randomised 1:1 (block randomisation stratified by age and gender) to either attend the indoor event for 5 hours or go home. Nasopharyngeal specimens used for Ag-RDT screening were analysed by real-time reverse-transcriptase PCR (RT-PCR) and cell culture (Vero E6 cells). 8 days after the event, a nasopharyngeal swab was collected and analysed by Ag-RDT, RT-PCR, and a transcription-mediated amplification test (TMA). The primary outcome was the difference in incidence of RT-PCR-confirmed SARS-CoV-2 infection at 8 days between the control and the intervention groups, assessed in all participants who were randomly assigned, attended the event, and had a valid result for the SARS-CoV-2 test done at follow-up. The trial is registered at ClinicalTrials.gov, NCT04668625.
FINDINGS
Participant enrollment took place during the morning of the day of the concert, Dec 12, 2020. Of the 1140 people who responded to the call and were deemed eligible, 1047 were randomly assigned to either enter the music event (experimental group) or continue with normal life (control group). Of the 523 randomly assigned to the experimental group, 465 were included in the analysis of the primary outcome (51 did not enter the event and eight did not take part in the follow-up assessment), and of the 524 randomly assigned to the control group, 495 were included in the final analysis (29 did not take part in the follow-up). At baseline, 15 (3%) of 495 individuals in the control group and 13 (3%) of 465 in the experimental group tested positive on TMA despite a negative Ag-RDT result. The RT-PCR test was positive in one case in each group and cell viral culture was negative in all cases. 8 days after the event, two (<1%) individuals in the control arm had a positive Ag-RDT and PCR result, whereas no Ag-RDT nor RT-PCR positive results were found in the intervention arm. The Bayesian estimate for the incidence between the experimental and control groups was -0·15% (95% CI -0·72 to 0·44).
INTERPRETATION
Our study provides preliminary evidence on the safety of indoor mass-gathering events during a COVID-19 outbreak under a comprehensive preventive intervention. The data could help restart cultural activities halted during COVID-19, which might have important sociocultural and economic implications.
FUNDING
Primavera Sound Group and the #YoMeCorono Initiative.
TRANSLATION
For the Spanish translation of the abstract see Supplementary Materials section.
Identifiants
pubmed: 34051886
pii: S1473-3099(21)00268-1
doi: 10.1016/S1473-3099(21)00268-1
pmc: PMC8457773
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04668625']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1365-1372Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests PS is an employee and stockholder of Primavera Sound, sponsor of the study. All other authors declare no competing interests.
Références
J Infect Dis. 2020 Oct 13;222(10):1635-1640
pubmed: 32840606
Science. 2021 Jan 8;371(6525):126-127
pubmed: 33414210
Phys Fluids (1994). 2021 Feb 1;33(2):023301
pubmed: 33746488
Nat Commun. 2021 Aug 19;12(1):5096
pubmed: 34413294
Clin Infect Dis. 2021 Nov 2;73(9):e3098-e3101
pubmed: 33367619
N Engl J Med. 2021 Feb 18;384(7):671-673
pubmed: 33503337
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Travel Med. 2020 Aug 20;27(5):
pubmed: 32520993
Nature. 2021 Feb;590(7845):202-205
pubmed: 33564189
J Clin Virol. 2020 Aug;129:104501
pubmed: 32619959
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Nat Med. 2020 Nov;26(11):1714-1719
pubmed: 32943787
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
Front Pharmacol. 2021 Mar 25;12:646676
pubmed: 33841165
Clin Infect Dis. 2021 Nov 2;73(9):e2861-e2866
pubmed: 33479756
J Infect. 2021 May;82(5):186-230
pubmed: 33421447
Clin Infect Dis. 2021 Aug 16;73(4):e860-e869
pubmed: 33104776
PLoS Biol. 2020 Nov 12;18(11):e3000897
pubmed: 33180773